clinical trial · NCT00613106
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
Amgen·phase3·completed·n = 179
OsteoarthritisRheumatoid ArthritisChronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue PainHZT-501Ibuprofen
brief summary
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.
started
Sep 1, 2007
primary completion
Oct 1, 2008
completion
Oct 1, 2008
last updated
Dec 17, 2024
detailed description
Subject who have completed the 24-week Treatment Period of Horizon Protocol HZ-CA-301 or HZ-CA-303 without developing an upper gastrointestinal ulcer and who are expected to continue to require daily administration of an NSAID for the next 6 months will receive treatment with the same study medication received while participating in HZ-CA-301 or HZ-CA-303.
Study with completed results acquired from Horizon in 2024.
official title
Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol